{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-012003","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.930264+00:00","generated_at":"2026-05-15T23:59:04.412082+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vericel Q4 2025 total revenue $92.9M (+23% YoY); FY25 net income up 59% to $16.5M","bullets":["Q4 total revenue $92.9M (+23% YoY); MACI revenue $84.1M (+23%); burn care $8.8M.","FY25 total revenue $276.3M (+16%); MACI revenue $239.5M (+21%); net income $16.5M ($0.32 diluted EPS).","Q4 adjusted EBITDA $37.3M (40% margin); FY25 adjusted EBITDA $70.9M (26% margin).","FY26 guidance: total revenue $316-326M, MACI revenue $280-286M, gross margin ~75%, adj. EBITDA margin ~27%.","Record Q4 MACI implants, biopsies, and implanting surgeons; MACI sales force expansion completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-012003","json":"https://secwatch.observer/filing/0001628280-26-012003.json","markdown":"https://secwatch.observer/filing/0001628280-26-012003.md","text":"https://secwatch.observer/filing/0001628280-26-012003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828026012003/0001628280-26-012003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828026012003/vcel-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:59:04.412082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}